NCT01626339

Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University of Malaya · Academic / Other
• Sex: All
• Age: 20 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE). Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

Conditions

• Age Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Intravitreal Ranibizumab
DRUG	Intravitreal bevacizumab

Timeline

• Start date: 2012-04-01
• Primary completion: 2012-06-01
• First posted: 2012-06-22
• Last updated: 2012-06-22

Locations

1 site across 1 country: Malaysia